Literature DB >> 879752

Response of influenza virus-infected mice to selected doses of ribavirin administered intraperitoneally or by aerosol.

R F Berendt, J S Walker, J W Dominik, E L Stephen.   

Abstract

The effects of graded doses of ribavirin administered either by aerosol or intraperitoneally were compared in influenza virus-infected mice. The median effective dose values (based upon percent survival) were 3.3 and 15.8 mg/kg per day for the aerosol and intraperitoneal routes, respectively. Lung lesion scores and titer of virus were lower after aerosol than intraperitoneal therapy.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 879752      PMCID： PMC352131          DOI： 10.1128/AAC.11.6.1069

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  3 in total

1.  Efficacy of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide against influenza virus infections in mice.

Authors:  F E Durr; H F Lindh; M Forbes
Journal:  Antimicrob Agents Chemother       Date:  1975-05       Impact factor: 5.191

2.  Therapeutic effects of ribavirin given by the intraperitoneal or aerosol route against influenza virus infections in mice.

Authors:  E L Stephen; J W Dominik; J B Moe; J S Walker
Journal:  Antimicrob Agents Chemother       Date:  1976-09       Impact factor: 5.191

3.  Suppression by 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) of influenza virus-induced infections in mice.

Authors:  G P Khare; R W Sidwell; J T Witkowski; L N Simon; R K Robins
Journal:  Antimicrob Agents Chemother       Date:  1973-04       Impact factor: 5.191
  3 in total
  8 in total

Review 1.  Biochemistry and clinical applications of ribavirin.

Authors:  B E Gilbert; V Knight
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

Review 2.  Ribavirin and inosiplex: a review of their present status in viral diseases.

Authors:  T W Chang; R C Heel
Journal:  Drugs       Date:  1981-08       Impact factor: 9.546

3.  Sensitive radioimmunoassay for the broad-spectrum antiviral agent ribavirin.

Authors:  R K Austin; P E Trefts; M Hintz; J D Connor; M F Kagnoff
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

4.  Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase).

Authors:  D M Ryan; J Ticehurst; M H Dempsey; C R Penn
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

5.  Inhibition of lymphocyte proliferative responses by ribavirin.

Authors:  D L Peavy; W C Koff; D S Hyman; V Knight
Journal:  Infect Immun       Date:  1980-08       Impact factor: 3.441

Review 6.  Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead.

Authors:  Tony Velkov; Nusaibah Abdul Rahim; Qi Tony Zhou; Hak-Kim Chan; Jian Li
Journal:  Adv Drug Deliv Rev       Date:  2014-11-12       Impact factor: 15.470

7.  Determining Ribavirin's mechanism of action against Lassa virus infection.

Authors:  Paola Carrillo-Bustamante; Thi Huyen Tram Nguyen; Lisa Oestereich; Stephan Günther; Jeremie Guedj; Frederik Graw
Journal:  Sci Rep       Date:  2017-09-15       Impact factor: 4.379

8.  Efficacy of Favipiravir Alone and in Combination With Ribavirin in a Lethal, Immunocompetent Mouse Model of Lassa Fever.

Authors:  Lisa Oestereich; Toni Rieger; Anja Lüdtke; Paula Ruibal; Stephanie Wurr; Elisa Pallasch; Sabrina Bockholt; Susanne Krasemann; César Muñoz-Fontela; Stephan Günther
Journal:  J Infect Dis       Date:  2015-11-03       Impact factor: 5.226
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.